Evaluation of <i>in vitro</i> efficacy of aztreonam-nacubactam and cefepime-nacubactam against clinical isolates of <i>Stenotrophomonas maltophilia</i>
We evaluated the <i>in vitro</i> activity of aztreonam-nacubactam (ATM-NAC) and cefepime-nacubactam (FEP-NAC) against 53 clinical isolates of <i>Stenotrophomonas maltophilia</i> from blood cultures. Minimum inhibitory concentrations (MICs) were determined via broth microdilution. While ATM-NAC showed more significant MIC reduction, FEP-NAC also remarkably decreased MICs, despite cefepime being a substrate for L1 β-lactamase. These findings suggest the potential of β-lactam-NAC combinations as promising alternatives, warranting further <i>in vivo</i> studies to confirm clinical applicability.
Authors
- Hiroaki Kubota (ORCID: https://orcid.org/0000-0002-6339-8568)
- Rika Inose
- Yoshifumi Uwamino (ORCID: https://orcid.org/0000-0001-9398-9599)
- Wataru Aoki (ORCID: https://orcid.org/0000-0002-3118-9390)
- Ho Namkoong (ORCID: https://orcid.org/0000-0001-6181-4284)
- Hiromichi Matsushita (ORCID: https://orcid.org/0000-0002-1629-6630)
- Yuka Kamoshita
- Mika Nagata
Institutions
- Keio University (JP)
- Tokyo Metropolitan Institute of Public Health (JP)
- Keio University Hospital (JP)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1128/aac.00755-25
- Primary Topic
- Infections and bacterial resistance
- Type
- article
- Field-Weighted Citation Impact
- 0.00